Table 4 Sequential measurements of clinical efficacy outcomes
Variables | Baseline | Week 1 | Week 2 | Week 6 | Week 12 | Week 24 |
|---|---|---|---|---|---|---|
Estimated marginal means (SE) | ||||||
HDRS | ||||||
 Mirtazapine | 23.0 (1.2) | 19.0 (1.3) | 15.5 (1.3) | 9.6 (1.4) | 9.3 (1.5) | 5.9 (1.6) |
 SSRIs | 23.1 (0.9) | 19.2 (0.9) | 16.9 (0.9) | 12.9 (1.0) | 9.5 (1.0) | 5.4 (1.1) |
  Sertraline | 23.2 (1.1) | 19.1 (1.2) | 16.3 (1.1) | 12.1 (1.2) | 8.7 (1.3) | 5.3 (1.4) |
  Paroxetine | 22.9 (1.5) | 19.4 (1.5) | 17.8 (1.5) | 14.6 (1.7) | 11.2 (1.8) | 5.8 (2.0) |
SDS | ||||||
 Mirtazapine | 56.0 (1.7) | 52.4 (1.8) | 46.6 (1.8) | 44.0 (1.9) | 43.7 (2.1) | 38.0 (2.2) |
 SSRIs | 57.6 (1.3) | 54.8 (1.3) | 52.8 (1.3) | 48.7 (1.4) | 44.9 (1.5) | 41.8 (1.6) |
  Sertraline | 57.4 (1.6) | 54.1 (1.7) | 51.2 (1.6) | 47.2 (1.7) | 42.4 (1.8) | 40.3 (1.9) |
  Paroxetine | 57.9 (2.1) | 56.1 (2.1) | 55.0 (2.1) | 51.4 (2.3) | 49.8 (2.5) | 44.5 (2.8) |
AIS | ||||||
 Mirtazapine | 11.5 (0.9) | 8.4 (0.9) | 6.6 (0.9) | 5.8 (1.0) | 6.8 (1.1) | 5.0 (1.1) |
 SSRIs | 12.9 (0.6) | 10.2 (0.6) | 9.3 (0.6) | 7.5 (0.7) | 6.6 (0.7) | 5.5 (0.8) |
  Sertraline | 12.8 (0.8) | 10.0 (0.8) | 8.1 (0.8) | 6.9 (0.8) | 5.3 (0.9) | 4.6 (1.0) |
  Paroxetine | 13.1 (1.0) | 10.5 (1.0) | 11.3 (1.0) | 8.8 (1.2) | 9.2 (1.2) | 7.2 (1.4) |
CGI-S | ||||||
 Mirtazapine | 4.4 (0.2) | 3.8 (0.2) | 3.2 (0.2) | 2.8 (0.2) | 2.6 (0.2) | 1.8 (0.2) |
 SSRIs | 4.3 (0.1) | 4.0 (0.1) | 3.6 (0.1) | 3.1 (0.1) | 2.7 (0.1) | 2.1 (0.2) |
  Sertraline | 4.4 (0.2) | 4.0 (0.2) | 3.6 (0.2) | 3.0 (0.2) | 2.6 (0.2) | 2.1 (0.2) |
  Paroxetine | 4.2 (0.2) | 4.1 (0.2) | 3.6 (0.2) | 3.5 (0.2) | 3.0 (0.3) | 2.0 (0.3) |